Table 1.
Anticancer effects of ferulic acid based on in vitro studies.
Type of Cancer | Cell Lines | Effects | Mechanisms | Concentration | References |
---|---|---|---|---|---|
Melanoma | Murine B16 | - | ↓ melanin production, ↓ tyrosinase activity, ↓ casein kinase 2 (CK2), ↑ p- tyrosinase | 25 and 50 µM | [75] |
A375, CHL-1, SK-MEL-2, B16F10 | Anti-angiogenic | ↓ proliferation, migration and tube formation, ↓ fibroblast growth factor 1 (FGF1), ↓ FGFR1, ↓ PI3K, ↓ protein kinase B (Akt) signaling, ↓ PI3K-Akt pathway, ↑ (HUVEC) Growth, ↓ VEGF-A, FGF1, FGF2, PDGF-α, PDGF-β and phosphatidylinositol-glycan biosynthesis class f protein (PIGF) | 0, 2.5, 5, 10, 20, 30, 40 μM | [43] | |
Sarcoma | S180 | Ameliorating oxidative stress injury | ↓ diosbulbin B-induced liver injury, ↓ ALT and AST activities, Ferulic acid reverses diosbulbin B-decreased CuZn-SOD and CAT enzymatic activities and mRNA expression | - | [76] |
Osteosarcoma | 143B and MG63 | Induces apoptosis | ↓ proliferation, ↑ G0/G1 phase arrest, ↓ CDK 2, CDK 4, CDK 6, ↑ Bax, ↓ Bcl-2, ↑ caspase-3 activity, ↓ PI3K/Akt activation | 0,10,30,100 and 150 µM | [77] |
Thyroid | TT cells | Induces apoptosis | ↓ invasion, migration and colony formation, ↓ URG4/URGCP (upregulated gene-4/upregulator of cell proliferation), ↓ CCND1, CDK4, CDK6, BCL2, MMP2, and MMP9, ↑ p53, PARP, PUMA, NOXA, BAX, BID, CASP3, CASP9 and TIMP1 | 50, 75, 100, 150, 200, 300, 400, 500, 750 μM and 1 mM | [78] |
Breast | MDA-MB 231 | Induces apoptosis | ↓ proliferation, ↑ apoptotic cells, ↓ percentages of cells in G0/G1 phases by TQ, ↓ in %ages of cells in the S phase by FA | Thymoquinone (TQ) and Ferulic Acid (FA) 25 μM TQ + 250 μM FA, 50 μM TQ + 350 μM FA, 50 μM TQ + 450 μM FA, 100 μM TQ + 350 μM FA, 100 μM TQ + 450 μM FA) | [79] |
MCF7 and 4T1 | Induces apoptosis | ↓ viability, structural changes in cancer cells as compared to normal cells, ↑ apoptosis, ↑ lipid peroxidation, ↑ mitochondrial damage, ↑ cell death | FA-Nanosponges 5, 10, 20, 40, 80, 125, 250, 500, 750, and 1000 µM | [80] | |
MDA-MB-231 | - | ↓ S phase, ↑ antiproliferative effects, ↑ sensitivity to UV treatment | 0–10 µM | [81] | |
MDA-MB-231 | Induces apoptosis and inhibits metastasis | ↓ viability, ↑ apoptosis, ↓ metastatic potential, reversal of epithelial-mesenchymal transition (EMT), ↑ caspase-3, ↓ migration across the wound edges, ↓ migration, ↓ vimentin, ↑ E-cadherin | 3, 10, 30 and 100 µM | [49] | |
MCF-7, MDAMB-231 and HS578T | Induces apoptosis | ↓ proliferation, ↑ cytotoxicity, ↑ p53, ↑ Bax, ↑ caspase-9 | 0–75 μM | [82] | |
Lung | A549 | Induces apoptosis | ↓ proliferation, ↓ oxidative stress, ↓ GSH, ↑ Keap1, ↓ Nrf2 nuclear level, ↑ apoptotic population, ↓ p-p38 MAPK level, ↓ activation of Akt/MAPK, ↓ p-STAT3, ↓ Cox-2, ↓ MMP-9 and VEGF, ↓ PECAM1, ↑ arrest at at G2/M phase, ↑ p53 and p21 protein, ↓ Cdc25C, ↑ active caspase 9,3, ↑ Bax, ↓ Bcl-2, ↑ radiation sensitivity | ferulic acid −10–400 μM, Gamma radiation 5, 7.5, 10 and 15 Gy (60 Co) | [83] |
A549 | Inhibits metastasis | ↓ Proliferation, ↑ G0/G1 phase (cell cycle arrest), ↓ migration and invasion, ↓ Bcl-2, ↑ Bax, ↑ Bax/Bcl-2 ratio, ↓ MMP-2 and MMP-9, ↓p- ERK and p-p38, it increased JNK expression, ↓ p-AKT, p-mTOR, p-MEK, and p-ERK | Ferulic acid derivative FXS-3 0.2–50 µM | [84] | |
Hepatocellular | HepG2 | Induces apoptosis | ↓ proliferation, ↓ oxidative stress, ↓ GSH, ↑ Keap1, ↓ Nrf2 nuclear level, ↑ apoptotic population, ↓ p-p38 MAPK level, ↓ activation of Akt/MAPK, ↓ p-STAT3, ↓ Cox-2, ↓ MMP-9 and VEGF, ↓ PECAM1, ↑ arrest at at G2/M phase, ↑ p53 and p21 protein, ↓ Cdc25C, ↑ active caspase 9,3, ↑ Bax, ↓ Bcl-2, ↑ radiation sensitivity | ferulic acid -10–400 μM, Gamma radiation 5, 7.5, 10 and 15 Gy (60 Co) | [83] |
Huh-7 and HepG2 | Induces apoptosis | ↓ viability, ↑ structural changes, ↑ROS, ↓ MMP, ↑ DNA damage, ↓ percent of cells in G0/G and G2/M, ↑ S phase, ↑ γH2AX, ↑ Bax, Bad, cleaved caspase 3 | ZnONPs with ferulic acid (ZnONPs-FAC) 0.05, 0.1, 1, 5, 10 and 20 µg/ml | [85] | |
Pancreatic | MIA PaCa-2 | Induces apoptosis | ↓ cell viability and colony formation, ↑ p53, Bax, PTEN caspase 3 and 9 | 150 μM, 200 μM, 300 μM, 400 μM, 500 μM, 750 μM and 1 mM | [86] |
Cervical | HeLa and Caski | Induces apoptosis | ↓ viability, ↑ DNA condensation, ↑ apoptosis, ↑ pro-caspase-3, pro-caspase-8, pro-caspase-9 and PARP, ↓ Bcl-2 and Mcl-1, ↑ Bax and ROS, ↓p-Akt and p-PI3K | 4–20 µM | [28] |
Hela and Caski | Induction of cell cycle arrest and autophagy | ↓ invasion, ↓ MMP-9, ↑ arrest in G0/G1 phase, ↑ p53 and p21, ↓ Cyclin D1 and Cyclin E, ↓ LC3-II, Beclin1 and Atg12-Atg5 | 0, 0.5, 1.0,1.5 and 2.0 mM | [32] | |
HeLa | - | ↓ Cell viability | ferulic acid nanohybrids 1, 5, 10, 20, 30, 40, and 50 μM | [87] | |
HeLa and ME-180 |
Enhances radiation effects by increasing lipid peroxidative markers | ↓ viability ↓ GSH, ↑ TBARS, CD and LHO, ↓ SOD, CAT and GPx, ↑ DNA damage, ↑ intracellular ROS levels (results by ferulic acid + irradiation in comparison with radiation or ferulic acid treatment alone) | ferulic acid (1, 5, 10, 20, 30 and 40 µg/mL) + radiation (2, 4, 6, 8, 10, 12 and 15 Gy) | [88] | |
Prostate | PC-3 | Induces apoptosis | ↓ proliferation, ↑ ATR, ATM, CDKN1A, CDKN1B, E2F4, RB1, and TP53 (Gene expression), ↓ CCND1, CCND2, CCND3, CDK2, CDK4, and CDK6 (gene expression) ↓ CDK4 and BCL2 (protein expression), ↓ invasion and colony formation | 20, 30, 50, 75, 100, 150, 200, 250, 300, 350, 500, 750, 900 µM, 1, 2 mM | [25] |
LNCaP | Induces apoptosis | ↓ proliferation, ↑ CASP1, CASP2, CASP8, CYCS, FAS, FASLG, and TRADD (gene expression), ↓ BCL2 and XIAP (gene expression), ↓CDK4 and BCL2 (protein expression), ↓ invasion and colony formation | 20, 30, 50, 75, 100, 150, 200, 250, 300, 350, 500, 750, 900, 1000 and 2000 µM | [25] | |
Colorectal | HCT- 116 and HT-29 | Induces apoptosis | ↑ antiproliferative effects, ↑ arrest at the G1 phase, ↓ S phase, ↑ Early apoptotic cells, ↑ Caspase 3, 8, and 9 activity | 0,0.25,0.5,1.0 and 1.5 mM | [89] |
HCT116 | Induces apoptosis | ↓ proliferation, ↑ p15 (mRNA level) | Ferulic acid-bound resveratrol- 0, 0.625, 1.25, 2.5, 5, 10 and 20 µM | [90] |